STD Update for Clinicians and Counselors

Satellite Conference Wednesday, March 10, 2004 2:00-4:00 p.m., Central Time

Produced by the Alabama Department of Public Health Video Communications Division

Faculty

Donna Meyers, MSN, CNS

Emory Regional Training Center Atlanta, Georgia

Objectives

- Describe the role of the women's health programs in screening for STDs/HIV.
- Identify infection trends, causative organisms, incubation period, s/s, diagnosis, complications and treatment for common STDs and HIV.
- List three factors for and three preventive measures against acquiring a STD and HIV.

Objectives (continued)

- Discuss the relationship between genital warts and cervical cancer.
- Discuss the relationship among fertility, ectopic pregnancy, chronic pelvic pain, STDs and HIV and the neonate.
- Describe effective counseling measures for pre and post test counseling and disclosure.

Women's Health Programs

- · Provide client friendly services
- Establish rapport with patient population to facilitate communication and elicit accurate sexual disease history
- Assess client accurately and refer to other community resources
- Participate in ongoing educational seminars

Sexually Transmitted Diseases Special Population

- Women suffer disproportionately from STDs/HIV
- · Adolescents are at high risk for STDs/HIV
- · Persons with multiple sex partners
- · Commercial sex workers

Sexually Transmitted Diseases Special Population (continued)

- · Men who have sex with men (MSM)
- Intravenous drug users
- · Individuals that practice unsafe sex
- Individuals with a history of previous STD/HIV infections
- Unplanned pregnancy

Special Population

- Women at highest risk for most STDs/HIV
 - -Sexually active
 - Women accounted for more than 32% of adult cases of AIDS in the U.S.
 - -1999 study, Minkoff found that of 262 HIV infected women, 46.9% had at least one incidence of a gynecologic condition

Special Population Adolescents

- A quarter of all new STD cases occur in ages 15-19 and 2/3 of all cases occur in ages 15-24
- More likely to have multiple partners
- More likely to have unprotected intercourse
- Female teenagers are also more susceptible to cervical infections
- Chlamydia is more common among teenagers

Special Population Commercial Workers

- Multiple partners
- More likely to engage in risky sexual acts
- · More likely to use illicit substances
- Less likely to have access to healthcare

Patient Centered Counseling and Testing

- School based Chlamydia screening and treatment program with urine LCR testing
- Outreach programs-mobile vans to treat and screen, health fairs
- Patient delivered medication programs for partners' treatment

Patient Centered Counseling Testing-Screening/Techniques

- Screener needs thorough knowledge of STDs
- Thorough knowledge of facility and state laws
- · Development of an effective screening tool

Patient Centered Counseling Testing-Screening/Techniques

(continued)

- · Utilize effective testing methods
- · Non-judgmental, non bias attitude
- Provide for a comfortable, workable and confidential testing location

Patient Centered Counseling Screening Tool

- Work the tool, don't let the tool work you
- · Just the facts
- Anonymous
- · Age, gender, socially appropriate
- · Screen for unhealthy lifestyle practices

STD – Screening/Testing Special Population

- Routinely screen all sexually active women age < 25 for all STDs, whether or not they are pregnant
- Personal risk depends on the number of risk markers
- Screening early in pregnancy provides increased opportunities to improve pregnancy outcome

STD – Screening/Testing Special Population

(continued)

 The optimal interval for re-screening women should be based on complaints, changes in sexual partners, young age and other risks

Sexually Transmitted Diseases

- STDs are very common-more than 16 million new cases annually
- · STDs have serious conscious
- STD treatment helps prevent the spread of HIV
- STDs are preventable
- Complex interaction of medical, social, economical and biological factors

Sexually Transmitted Diseases

(continued)

- STDs are the results of more than 40 different microbes
- Human genital tract is the reservoir
- STDs rarely survive outside the body
- Transmission occurs during sex, gestation, or birth

STD Syndromes

• Genital Ulcer

Warts

Herpes/HPV

Discharge

Gonorrhea

Chlamydia

Vaginitis

Trichomoniasis

Genital Ulcer - HPV Warts

• Organism: Virus-Human Papilloma Virus

• Prevalence: >30% of population

• Transmission: Direct sexual contact


• Incubation: Average 2-3 months

Genital Ulcer - HPV Warts

(continued)

- Symptoms: Non-cancer types of HPV 6,11 are raised, rough or smooth "bumps" on the genitalia that may itch/burn. Cancer HPV 16, 18, are microscopic and have no symptoms
- External warts are a marker of sexual risk
- Diagnosis: Clinical Manifestations (acetic acid), abnormal Pap Smear







Genital Warts - HPV Complications

- Increase risk of cervical cancer
 - Types that cause cervical cancer, don't usually cause warts
- Reproductive
- Cosmetic
- Self-esteem

Genital Warts-HPV Treatment

Treatment: All have high failure rates
 Observation- 20% spontaneous regress
 Destructive- cryotheraphy (freeze), laser
 surgery,TCA

Immune system mediators- interferon alpha, Tagament, Aldara (home treatment) Complications: Cervical Cancer- HPV found in over 90% Ca. Microscopic HPV types 16, 18, 45, 56



Herpes (HSV II)

• Syndrome: Genital Ulcers

• Organism: Virus-Herpes Simplex Virus

Prevalence: 1 million new cases annually
 -(> 45 million total in U.S.)

















Herpes (HSV II) Complications

- Highly contagious
- Chronic, persistent, often debilitating ulcers
- Reproductive
- Cosmetic
- · Self-esteem
- · Life changing
 - -Sexuality
 - -Neonatal

Herpes: Treatment

- Treatment: No cure for herpes but . . .
 - Antiviral medications can decrease severity and frequency
 - -Acyclovir (Zovirax) -
 - -400mg PO t.i.d. for 7-10 day
 - -200 mg PO 5x/day for 7-10 days
 - -Famciclovir (Famvir)-
 - -250 mg PO t.i.d. for 7-10 days

Herpes: Treatment (continued)

-Valcyclovir (Valtrex)-

-1000mg PO b.i.d.for 7-10 days

Different dosages for initial treatment vs. recurrent or suppressive treatment

Complications: Neonatal herpes and severe HSV infections with AIDS

Gonorrhea

- · Syndrome: Urethral or Cervical discharge
- Name: AKA "clap" and also "brunt"
- Organism: bacteria-Neisseria gonorrhea
- Prevalence: very common


 (10,000 cases in the U.S.)


Gonorrhea (continued)

- Transmission: direct contact with discharge
- Incubation: 3-5 days
- Symptoms: yellow discharge that burns>30% male have no symptoms
 - •>50% women have no symptoms

Gonorrhea: FYI

- Ancient disease with written accounts as far back as 2637 BC
- U.S. rates increased in the mid-1960s to the mid-1970s
- Popularity had been over shadowed by the Chlamydia and HSV in the 80s
- Presently there are a little more than 1 million new cases annually
- Heterosexual, minority, illicit drug use and prostitution





Gonorrhea: Treatment

- Treatment: Antibiotics (one pill or shot)
 - -Suprax 400mg PO STAT (Cefixime)
 - no longer available
 - -Ciprofloxacin 500mg PO STAT
 - -Azithromaycin 2gm PO STAT
 - -Rocephin 250mg IM STAT (Ceftriaxone)
 - •Ok with pregnancy

Gonorrhea: Complications

- Sterility
- Infertility (PID)
- Neonatal-illness and blindness
- · Increase risk of contracting HIV

Chlamydia


- C.psittact, C. pneumoniae, and C.trachomatis
- C.trachomatis- human reservoir
 - •Ocular
 - Pulmonary
 - •Enteric
 - Genital tract

Chlamydia (continued)

- In the early 20thcentury thought to have had a viral origin
- Bacteria with both a RNA and DNA complex
- Asymptomatic
 - •Approximately 70%-80% women
 - •Approximately 50% men
- Syndrome: Discharge
- Organism: Bacteria

Chlamydia (continued)

- Prevalence: 3 million annually
- Transmission: Direct sexual contact
- Incubation: 1-3 weeks
- Symptoms: Most asymptomatic
 - -Men: clear-white urethral discharge that may burn when urinating in the morning
 - -Women: post-coital bleeding, abdominal pain, mucopurulent cervicitis





Chlamydia: Complications

- 30%-50% of cases of nongonococcal urethritis
- · Increased risk of HIV
- Endocervicitis
- Pelvic Inflammatory Disease (PID)
- Infertility
- Ectopic pregnancy
- Prematurity
- Increase perinatal mortality

Chlamydia: Complications

(continued)

- 60% of infants born to endocervically infected mothers are infected at the time of vaginal delivery
- Onset of Conjunctivitis-14 days post delivery
- Chlamydia pneumonia-4 to 7 weeks following delivery

Chlaymdia: Treatment

- Antibiotics
 - -Azithromcyin 1gm PO
 - -Doxycycline 100mg PO x 7 days

STD- Testing Technologies

Batch Testing -

Laboratory based test that include:

- Culture
- •NAAT's
- Nucleic acid hybridization

Point of Care Test

Gram Stain

Culture Test

 N. Gonorrhoeae Culture-specimens are streaked on a selective medium. These mediums are inoculated and incubated at 35-36.5 degrees C in a atmosphere supplemented with 5% co2 and examined at 24-hour intervals for, < 72 hours. Chocolatized equine and bovine blood are used in the medium to support the growth of the gonococcus.

Culture Test (continued)

 C.trachomatis Culture- inoculation of a confluent monolayer of susceptible cells. These cells are then collected and transported. After 48-72 hours of intracytoplasmic inclusion that contains a substantial numbers of C. tracohmatis reticulate body. These inclusions are then detected by fluorescein antibody staining that is specific for the major outer membrane protein (MOMP) of C.trachomatis.

NAATs- The Gen-Probe APTIMA

- Uses transcription-mediated amplification to detect a specific 23s ribosomal RNA target
- Majority of commercial NAATs have been FDA cleared to detect endocervical swabs from women and urethral swabs from men and urine from women and men (facilitates screening venues)

NAATs- The Gen-Probe APTIMA

(continued)

 Rectal and oropharyngeal specimen collection with NAATs has limited evaluation and is not recommended

Nucleic Acid Hybridization (Nucleic Acid Probe) Test

- Gen-Probe PACE-DNA probe zeros in on a specific sequence of C.trachomatis or N.gonorrhoeae rRNA hybridization with a similar rRNA that is present in the specimen
- Digene Hybrid Capture II assays-are specific for DNA sequence of C.trachomatis and N. gonorrhoeae

Nucleic Acid Hybridization (Nucleic Acid Probe) Test (continued)

- Test advantages-Both tests allow storage and transport of specimen for ≤ 7 days without refrigeration before processing by the lab
- The only two nucleic assay tests FDAcleared for C.trachomatis and N.gonorrhoeae testing

Point of Care Test N.gonorrhoeae

 Gram stain- the key tool for diagnosis of gonococcal urethritis in men. A gram stain for the presumptive diagnosis of N.gonorrhoeae infections is performed on thin smears of urethral exudate from men and is presumptively positive if the smear contains typical Gram-negative diplocicci within polymorphonuclear (pmn) leukocytes.

Point of Care Test C.trachomatis

- Test can be performed within 30 minutes
- Does not require expensive or sophisticated equipment and are packaged as single unit test
- Test is classified under CLIA as test of moderate complexity

Point of Care Test C.trachomatis (continued)

- Similar to EIAs these tests use antibodies against LPS that detect all three Chlamydia species
- Point of Care Test should not be selected if it is performed in the lab after the patient's visit

Trichomoniasis

- Syndrome: Vaginitis
- Organism: Protoza-Trichmoniasis vaginalis
- Prevalence: 5 million cases annually
- Transmission: sexually-rarely fomite
- Symptoms: Vaginal discharge that is frothy, white clear with itching and malodor



Trichomoniasis: Complications

- · Increase HIV risk
- Prematurity
- Documented cases of PID (possible) very rare

Trichomoniasis

• Treatment: Metronidazole 2gm PO

HIV

What is it and how does it make people sick?

HIV and AIDS

- HIV stands for "Human Immunodeficiency Virus"
- HIV is a virus (germ) that infects blood and damages your ability to fight disease
- AIDS stands for "Acquired Immune Deficiency Syndrome"
- AIDS is the disease caused by HIV.
 People with AIDS lose their ability to fight germs that can make them sick

How Do You Get HIV?

- You can get HIV from the blood or certain other body fluids of an infected person
- When fluid that is infected with HIV gets into your blood, then you can get infected too
- HIV can be in:

Blood

Vaginal fluid

Semen/sperm

Breast milk

You Can Be Tested for HIV

- · A simple blood test
- Unless it has been 6 months since you became infected, a blood test may not show HIV. Retest every 3 months if you are at risk
- The standard test looks for a reaction to HIV from your immune system

Your Body's Immune System

- The immune system works in the body to fight germs and keep you healthy
- T cells are the "soldiers" of your immune system
- T cells recognize germs in your body, and they work with other cells to destroy them

How Your Immune System Fights HIV

- "Killer" T cells (CTLs) can find and destroy cells that are infected with HIV
- HIV infects "helper" T cells (CD4 cells)
- Helper T cells order "killer" T cells to do their job
- When the "helper" T cells are destroyed by HIV, the immune system does not know how to fight germs

There Is A War Between Your Body and HIV

- Billions of viruses are created every day
- HIV attacks and infects your T cells
- Your immune system attacks and kills the T cells that have been infected with HIV

HIV Eventually Drains Your Immune System

- When T cells are killed by HIV, they are replaced, but not as quickly as they are being killed
- · HIV reproduces very fast
- Eventually, T cells fall too far behind and then cannot do their job of fighting germs

Treatment Slows the Dog

- Treatment slows down the dog (HIV) so it can't run as fast
- When the dog runs slower, your viral load goes down
- When your viral load is down, you are doing better against HIV

When Viral Load Goes Up, Immunity Goes Down

- When there are more HIV germs, they infect and kill more T cells
- T cells are needed to fight HIV and other germs
- Eventually your body cannot produce T cells as fast as they are killed by HIV

Three Main Types of Treatment Drugs

1. NRTIs (nucleoside reverse transcriptase inhibitors)

Work by interfering with the material that allows HIV to reproduce

2. NNRTIs (Non-NRTIs)

Attack HIV in the same place as NRTIs but in a different way

3. Pls (protease inhibitors)

Stop HIV from being assembled

Combination Therapy

The best way to treat HIV is by using more than one kind of drug at a time.

Protease Inhibitor + NRTI + NNRTI

HIV: Treatment Fusion Inhibitors

- Fuzeon- Condom for the CD4 cells
 - -Inhibits the fusion of the HIV virus into the CD4 cells
 - -Combination therapy
 - -Adult/Children (age >6)

HIV: Vertical Transmission

- 076 AZT study-decreased transmission rate by 70%
- 419 infants
- · Combination therapy

HIV and Neonate

- DNA/PCR testing at birth
 - (+) Immediate retesting
 - (-) Test is repeated @ 4 months
- 18-24 months confirmatory testing for the clearance of maternal antibodies/ ELISA/WESTERBLOT

Antiretroviral therapy for all (+) babies Viral loads< 400 undetectable

Summary: HIV Infection Is A Disease of the Immune System

- · HIV is a virus that infects blood
- HIV is passed from one person to another through blood or certain body fluids
- HIV reproduces very fast and attacks and kills T cells
- T cells are needed to fight HIV and other germs

Summary: HIV Infection Is A Disease of the Immune System (continued)

- Viral load measures how much HIV is in your blood and predicts how well you will do
- CD4 cell count measures how well your immune system fights germs

Confidentiality Practical Steps

- Avoid learning of contact
- · Have the client disclose
- Consider shifting disclosure task to someone else

HIV Confidentiality Statute

- · Disclosing reputation
- · Consequences of disclosing

STDs/HIV: Conclusion

- STDs/HIV are a significant public health problem. Healthcare professionals need to beware of advancements in treatments and screening methods.
 - -Urine screening (DNA amplification test)
 - -Mobile testing sites
 - -Outreach programs
 - -Patient education/condom distribution

STDs/HIV: Conclusion

(continued)

 The best treatment however remains prevention. Prevention involves the use of condoms and limiting numbers of sexual partners.

Upcoming Programs:

Preventing Sexual Coercion Among Adolescents (Part 2)

Thursday, March 18, 2004 2:00-4:00 p.m., Central Time

Chemical Risk Assessment in an Uncertain World

Tuesday, March 30, 2004 12:00-1:30 p.m., Central Time For a complete listing of programs, visit our website: www.adph.org/alphtn